G-CSF downregulates natural killer cell-mediated cytotoxicity in donors for hematopoietic SCT

Bone Marrow Transplantation

Volumn 47, Issue 1, 2012, Pages 73-81

  Su, Y C ^a,b   Li, S C ^b   Hsu, C K ^c   Yu, C C ^b,c   Lin, T J ^c   Lee, C Y ^c   Liao, H F ^c,d  

^a TZU CHI UNIVERSITY   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^c NATIONAL CHIAYI UNIVERSITY   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

cytotoxicity; granulocyte colony stimulating factor; mitogen activated protein kinases; natural killer cells; phosphatidylinositol 3 kinase; triosephosphate isomerase

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTATE DEHYDROGENASE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P85; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; WORTMANNIN;

ADULT; ALPHA CHAIN; ARTICLE; BETA CHAIN; CD34 SELECTION; CELL ACTIVITY; CELL ISOLATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DONOR; DOWN REGULATION; DRUG EFFECT; DRUG MEGADOSE; ENZYME PHOSPHORYLATION; ENZYME RELEASE; FEMALE; GENE; GENE EXPRESSION REGULATION; GRAFT VERSUS HOST REACTION; GRANULOCYTE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOREGULATION; INTRACELLULAR SIGNALING; LEUKOCYTE; LEUKOCYTE ACTIVATION; LYMPHOCYTE; MALE; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NEUTROPHIL; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DNA BINDING; T LYMPHOCYTE ACTIVATION; TRIOSEPHOSPHATE ISOMERASE GENE;

ADULT; ANDROSTADIENES; DOWN-REGULATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; FLAVONOIDS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNITY, CELLULAR; K562 CELLS; KILLER CELLS, NATURAL; MALE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; TISSUE DONORS; TOR SERINE-THREONINE KINASES; TRIOSE-PHOSPHATE ISOMERASE;

EID: 84855739275     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.22     Document Type: Article

References (36)

1. Kusano K, Ebara S, Tachibana K, Nishimura T, Sato S, Kuwaki T et al. A potential therapeutic role for small nonpeptidyl compounds that mimic human granulocyte colony-stimulating factor. Blood 2004; 103: 836-842. (Pubitemid 38129540)
2. Joshi SS, Lynch JC, Pavletic SZ, Tarantolo SR, Pirruccello SJ, Kessinger A et al. Decreased immune functions of blood cells following mobilization with granulocyte colony-stimulating factor: association with donor characteristics. Blood 2001; 98: 1963-1970.
3. Pavletic ZS, Joshi SS, Pirruccello SJ, Tarantolo SR, Kollath J, Reed EC et al. Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancy. Bone Marrow Transplant 1998; 21: 33-41. (Pubitemid 28043434)
4. Sloand EM, Kim S, Maciejewski JP, Van Rhee F, Chaudhuri A, Barrett J et al. Pharmacologic doses of granulocyte colonystimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood 2000; 95: 2269-2274. (Pubitemid 30167724)
5. Young HA, Ortaldo J. Cytokines as critical co-stimulatory molecules in modulating the immune response of natural killer cells. Cell Res 2006; 16: 20-24. (Pubitemid 43129305)
6. Chen YJ, Liao HF. NK/NKT cells and aging. Int J Gerontol 2007; 1: 65-76.
7. Chen YJ, Yu CC, Chen ST, Chen TY, Liao HF. Functional regulation and proteomic characterization of human natural killer cells through recombinant human granulocyte-colony stimulating factor treatment. Proteomics Clin Appl 2009; 3: 563-573.
8. Weitz-Schmidt G, Chreng S, Riek S. Allosteric LFA-1 inhibitors modulate natural killer cell function. Mol Pharmacol 2009; 75: 355-362.
9. Burt RK, Loh Y, Pearce W, Beohar N, Barr WG, Craig R et al. Clinical applications of blood-derived and marrowderived stem cells for nonmalignant diseases. JAMA 2008; 299: 925-936. (Pubitemid 351397068)
10. Russell N, Bessell E, Stainer C, Haynes A, Das-Gupta E, Byrne J. Allogeneic haemopoietic stem cell transplantation for multiple myeloma or plasma cell leukaemia using fractionated total body radiation and high-dose melphalan conditioning. Acta Oncol 2000; 39: 837-841.
11. Robertson NJ, Chai JG, Millrain M, Scott D, Hashim F, Manktelow E et al. Natural regulation of immunity to minor histocompatibility antigens. J Immunol 2007; 178: 3558-3565. (Pubitemid 46417622)
12. Nakamura R, Auayporn N, Smith DD, Palmer J, Sun JY, Schriber J et al. Impact of graft cell dose on transplant outcomes following unrelated donor allogeneic peripheral blood stem cell transplantation: higher CD34+ cell doses are associated with decreased relapse rates. Biol Blood Marrow Transplant 2008; 14: 449-457. (Pubitemid 351372753)
13. Malmberg KJ, Schaffer M, Ringdén O, Remberger M, Ljunggren HG. KIR-ligand mismatch in allogeneic hematopoietic stem cell transplantation. Mol Immunol 2005; 42: 531-534. (Pubitemid 39655964)
14. Rondelli D, Raspodiri D, Anasetti C, Bandini G, Re F, Arpinati M et al. Alloantigen presenting capacity, T cell alloreactivity and NK function of G-CSF-mobilized peripheral blood cells. Bone Marrow Transplant 1998; 22: 631-637. (Pubitemid 28486360)
15. Miller JS, Prosper F, McCullar V. Natural killer (NK) cells are functionally abnormal and NK cells are diminished in granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cell collections. Blood 1997; 90: 3098-3105. (Pubitemid 27444204)
16. Joshi SS, Lynch JC, Pavletic SZ, Tarantolo SR, Pirruccello SJ, Kessinger A et al. Decreased immune functions of blood cells following mobilization with granulocyte colony-stimulating factor: association with donor characteristics. Blood 2001; 98: 1963-1970.
17. Yokoyama WM, Riley JK. NK cells and their receptors. Reprod Biomed Online 2008; 16: 173-191. (Pubitemid 351291964)
18. Schlahsa L, Jaimes Y, Blasczyk R, Figueiredo C. Granulocytecolony- stimulatory factor: a strong inhibitor of natural killer cell function. Transfusion 2010; 51: 293-305.
19. Morel E, Bellón T. HLA class I molecules regulate IFNgamma production induced in NK cells by target cells, viral products, or immature dendritic cells through the inhibitory receptor ILT2/CD85j. J Immunol 2008; 181: 2368-2381.
20. Ryan MA, Nattamai KJ, Xing E, Schleimer D, Daria D, Sengupta A et al. Pharmacological inhibition of EGFR signaling enhances G-CSF-induced hematopoietic stem cell mobilization. Nat Med 2010; 16: 1141-1146.
21. Banovic T, MacDonald KP, Markey KA, Morris ES, Kuns RD, Varelias A et al. Donor treatment with a multipegylated G-CSF maximizes graft-versus-leukemia effects. Biol Blood Marrow Transplant 2009; 15: 126-130.
22. Puwada SD, Funkhouser WK, Greene K, Deal A, Chu H, Baldwin AS et al. NF-kB and Bcl-3 activation are prognostic in metastatic colorectal cancer. Oncology 2010; 78: 181-188.
23. Cesaro S, Chinello P, De Silvestro G, Marson P, Picco G, Varotto S et al. Granulocyte transfusions from G-CSFstimulated donors for the treatment of severe infections in neutropenic pediatric patients with onco-hematological diseases. Support Care Cancer 2003; 11: 101-106. (Pubitemid 36733819)
24. Vose JM, Ho AD, Coiffier B, Corradini P, Khouri I, Sureda A et al. Advances in mobilization for the optimization of autologous stem cell transplantation. Leuk Lymphoma 2009; 50: 1412-1421.
25. Hershman D, Neugut AI, Jacobson JS, Wang J, Tsai WY, McBride R et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 2007; 99: 196-205.
26. Verheyden S, Schots R, Duquet W, Demanet C. A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia 2005; 19: 1446-1451. (Pubitemid 41136340)
27. Segovis CM, Schoon RA, Dick CJ, Nacusi LP, Leibson PJ, Billadeau DD. PI3K links NKG2D signaling to a CrkL pathway involved in natural killer cell adhesion, polarity, and granule secretion. J Immunol 2009; 182: 6933-6942.
28. Kim N, Saudemont A, Webb L, Camps M, Ruckle T, Hirsch E et al. The p110delta catalytic isoform of PI3K is a key player in NK-cell development and cytokine secretion. Blood 2007; 110: 3202-3208. (Pubitemid 350106312)
29. Lagadari M, Lehmann K, Ziemer M, Truta-Feles K, Berod L, Idzko M et al. Sphingosine-1-phosphate inhibits the cytotoxic activity of NK cells via Gs protein-mediated signalling. Int J Oncol 2009; 34: 287-294.
30. Kawauchi K, Ihjima K, Yamada O. IL-2 increases human telomerase reverse transcriptase activity transcriptionally and posttranslationally through phosphatidylinositol 30-kinase/ Akt, heat shock protein 90, and mammalian target of rapamycin in transformed NK cells. J Immunol 2005; 174: 5261-5269. (Pubitemid 40593164)
31. Saemann MD, Haidinger M, Hecking M, Horl WH, Weichhart T. The multifunctional role of mTOR in innate immunity: implications for transplant immunity. Am J Transplant 2009; 9: 2655-2661.
32. Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 2009; 9: 324-337.
33. Wai LE, Fujiki M, Takeda S, Martinez OM, Krams SM. Rapamycin, but not cyclosporine or FK506, alters natural killer cell function. Transplantation 2008; 85: 145-149.
34. Plas DR, Rathmell JC, Thompson CB. Homeostatic control of lymphocyte survival: potential origins and implications. Nat Immunol 2002; 3: 515-521. (Pubitemid 34662302)
35. Chang M, Hamilton JA, Scholz GM, Elsegood CL. Glycolytic control of adjuvant-induced macrophage survival: role of PI3K, MEK1/2, and Bcl-2. J Leukoc Biol 2009; 85: 947-956.
36. Greinix HT, Worel N. New agents for mobilizing peripheral blood stem cells. Transfus Apher Sci 2009; 41: 67-71.